Chinese state fund invests in gene firm BGI


SYDNEY – The Chinese government has made an investment in BGI Genomics Co, a listed Chinese company that has supplied millions of COVID-19 tests globally as the gene firm seeks to fund exponential growth driven by the pandemic.

BGI Group, which runs a massive gene databank in China and has DNA sequencing contracts with health firms and universities worldwide, has in the past responded to claims from US security agencies that it is closely linked to the Chinese government…


Click here to view the original article.